With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

SYDNEY, Feb 11 (Reuters) - CSL Ltd (CSL.AX), opens new tab on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, a day ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

CSL Ltd (ASX: CSL) will report its 2026 half-year financial results this morning. The update comes as the company prepares for a change in senior leadership. Just after market close on Tuesday, CSL ...

SYDNEY--Australia-based pharmaceutical company CSL posted a steep decline in fiscal first-half profit, reflecting government policy changes, shifting public attitudes toward vaccines and one-off costs ...

Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL names Gordon Naylor as interim CEO after Dr Paul McKenzie's retirement, marking a new chapter for the ASX healthcare leader. Dr Paul McKenzie will retire as CEO and managing director, effective 10 ...

Add Yahoo as a preferred source to see more of our stories on Google. A 68-year-old Houston woman says she spent more than a year trying to find the source of water flowing into her backyard, only to ...